Synopsis Antimuscarinics are commonly used as a first-line pharmacologic treatment for urgency urinary incontinence (UUI) and overactive bladder (OAB). Antimuscarinics such as fesoterodine have optimal efficacy with manageable side effects. In this regard, the following article summarizes the results of fesoterodine, an FDA-approved drug in reducing UUI episodes. This week’s Journal Watch summarizes a trial “Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER,” published in International Journal of Clinical Practice .
Authors: S A Kaplan, L Cardozo, S Herschorn, et al. What was the need for this study? Fesoterodine is available in two doses, allowing physicians to titrate dosages for optimal efficacy and manageable side effect. Alternatively, some patients with overactive bladder (OAB) and not achieving optimal…
